293 related articles for article (PubMed ID: 31289930)
41. Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation.
Pagliuca S; Bommier C; Michonneau D; Meignin V; Salmona M; Robin M; Prata PH; Xhaard A; de Fontbrune FS; Feghoul L; Dhedin N; de Latour RP; Caillat-Zucman S; Goff JL; Socié G
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2490-2500. PubMed ID: 31421238
[TBL] [Abstract][Full Text] [Related]
42. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study.
Watanabe Y; Sasahara Y; Satoh M; Looi CY; Katayama S; Suzuki T; Suzuki N; Ouchi M; Horino S; Moriya K; Nanjyo Y; Onuma M; Kitazawa H; Irie M; Niizuma H; Uchiyama T; Rikiishi T; Kumaki S; Minegishi M; Wada T; Yachie A; Tsuchiya S; Kure S
Eur J Haematol; 2013 Sep; 91(3):242-248. PubMed ID: 23734904
[TBL] [Abstract][Full Text] [Related]
43. Incidence, risk factors, and clinical outcomes associated with Epstein-Barr virus-DNAemia and Epstein-Barr virus-associated disease in patients after haploidentical allogeneic stem cell transplantation: A single-center study.
Zhou L; Gao ZY; Lu DP
Clin Transplant; 2020 Jun; 34(6):e13856. PubMed ID: 32170765
[TBL] [Abstract][Full Text] [Related]
44. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
[TBL] [Abstract][Full Text] [Related]
45. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation.
Hoshino Y; Kimura H; Tanaka N; Tsuge I; Kudo K; Horibe K; Kato K; Matsuyama T; Kikuta A; Kojima S; Morishima T
Br J Haematol; 2001 Oct; 115(1):105-11. PubMed ID: 11722419
[TBL] [Abstract][Full Text] [Related]
46. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
[TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients.
Aalto SM; Juvonen E; Tarkkanen J; Volin L; Haario H; Ruutu T; Hedman K
Clin Infect Dis; 2007 Nov; 45(10):1305-9. PubMed ID: 17968825
[TBL] [Abstract][Full Text] [Related]
48. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.
Liu Q; Xuan L; Liu H; Huang F; Zhou H; Fan Z; Zhao K; Wu M; Xu L; Zhai X; Zhang F; Liu C; Sun J; Huang X
Am J Hematol; 2013 Jul; 88(7):550-5. PubMed ID: 23564232
[TBL] [Abstract][Full Text] [Related]
49. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
50. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
[TBL] [Abstract][Full Text] [Related]
51. Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 DNA in samples from transplant recipients by multiplex real-time PCR assay.
Wada K; Kubota N; Ito Y; Yagasaki H; Kato K; Yoshikawa T; Ono Y; Ando H; Fujimoto Y; Kiuchi T; Kojima S; Nishiyama Y; Kimura H
J Clin Microbiol; 2007 May; 45(5):1426-32. PubMed ID: 17376882
[TBL] [Abstract][Full Text] [Related]
52. Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell Transplantation.
Marzolini MAV; Wilson AJ; Sanchez E; Carpenter B; Chakraverty R; Hough R; Kottaridis P; Morris EC; Thomson KJ; Peggs KS
Transplant Cell Ther; 2021 Aug; 27(8):682.e1-682.e12. PubMed ID: 33962069
[TBL] [Abstract][Full Text] [Related]
53. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.
Liu L; Zhang X; Feng S
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1341-1349. PubMed ID: 29530767
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the artus Epstein-Barr virus (EBV) PCR kit and the Abbott RealTime EBV assay for measuring plasma EBV DNA loads in allogeneic stem cell transplant recipients.
Vinuesa V; Solano C; Giménez E; Navarro D
Diagn Microbiol Infect Dis; 2017 May; 88(1):36-38. PubMed ID: 28274502
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of Epstein-Barr virus-specific immunologic response in solid organ transplant recipients with an enzyme-linked ImmunoSpot assay.
Rittà M; Costa C; Sinesi F; Sidoti F; Di Nauta A; Mantovani S; Piceghello A; Simeone S; Ricci D; Boffini M; Solidoro P; Baldi S; Segoloni GP; Cavallo R
Transplant Proc; 2013 Sep; 45(7):2754-7. PubMed ID: 24034040
[TBL] [Abstract][Full Text] [Related]
56. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
57. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
Peric Z; Cahu X; Chevallier P; Brissot E; Malard F; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Milpied N; Coste-Burel M; Imbert-Marcille BM; Mohty M
Leukemia; 2011 Jun; 25(6):932-8. PubMed ID: 21350556
[TBL] [Abstract][Full Text] [Related]
58. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation.
Bordon V; Padalko E; Benoit Y; Dhooge C; Laureys G
Pediatr Transplant; 2012 Mar; 16(2):144-50. PubMed ID: 22288846
[TBL] [Abstract][Full Text] [Related]
59. [EBV quantification in children after allogeneic hematopoietic stem cell transplantation].
Hubácek P; Cinek O; Kulich M; Zajac M; Keslová P; Formánková R; Starý J; Sedlácek P
Cas Lek Cesk; 2006; 145(4):301-6. PubMed ID: 16639931
[TBL] [Abstract][Full Text] [Related]
60. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
